Results 121 to 130 of about 7,361 (221)
Case Report - Ocular myasthenia gravis coincident with thyroid ophthalmopathy [PDF]
, 2003 Graves' disease and myasthenia gravis are both auto-immune diseases and the coexistence of these two diseases is well recognized. Myasthenia gravis is more frequent in patients with thyroid disease.
A. Yaman, H. Yaman
core +2 more sources
Mycophenolate Mofetil (Cellcept) 10 Ocular Myasthenia Gravis [PDF]
, 2008 Immunosuppressive therapies (e.g., corticosteroids, azathioprine, eydosporine) have been used in ocular myasthenia gravis (OMG). Unfortunately effectiveness is limited by their variable efficacy, side effects and patient rolerana.
Aileen Antonio-Santos; Eric Eggenberger; Umar Farooq; Richard Freij
core
The Effect of Corticosteroids on the Progression of Ocular Myasthenia to Generalized Myasthenia [PDF]
, 1999 In previously published reports, 49% to 69% of patients with Ocular Myasthenia (OMG) will progress to Generalized Myasthenia Gravis (GMG without any medical intervention. Of the patients with only ocular manifestations at onset who later develop symptoms
Nicholas T. Monsul; Amy M. Knorr; Jonathan M. Goldstein; Robert L. Lesser
core
Peribulbar Corticosteroids for Ocular Myasthenia Gravis [PDF]
Background: Ocular myasthenia gravis is treated predominantly by oral medications, with the potential for systemic adverse effects. Successful treatment has been achieved using peribulbar dexamethasone.
Rachel Lasry, MSc, Marc Gotkine, MBBS, Joshua M. Kruger, MD, PhD
core
Ocular Myasthenia Gravis with Multiple Episodes of Spontaneously Remitting Symptoms [PDF]
, 2006 Myasthenia gravis is a chronic disease generally requiring lifelong treatment. Approximately 20% of patients with myasthenia gravis will have a spontaneous transitory or complete clinical remission during the course of their disease. Although a relapsing
K. Warden; W. Cornblath
core
Conversion Rate Of Ocular Myasthenia Gravis To Generalized Myasthenia Gravis [PDF]
, 2013 Ocular myasthenia gravis (OMG) is a common presentation to the neuro-ophthalmology clinic. Previous studies have reported that generalized myasthenia gravis (GMG) develops in 50% or more of patients presenting with OMG, usually within 2 years.
Lina Nagia; Khawla Abusamra; Eric R. Eggenberger
core
Primary Immunosuppresive Treatment of Ocular Myasthenia Gravis with Cyclosporine A [PDF]
, 1998 Immunosuppressive therapy for ocular myasthenia gravis (MG) has usually consisted of systemic corticosteroids or azathioprine. Although each drug can induce a remission, each has drawbacks. Cyclosporine A (CsA) has been demonstrated in a controlled trial
Preston C. Calvert
core
SAGE Open MedicineBackground: In Vietnam, there is limited research on the role of nerve conduction in myasthenia gravis and its association with clinical features. Objective: This study aims to describe the electrophysiological features in patients with myasthenia gravis.
Tho Kieu Anh Pham +7 more
doaj +1 more source
Screening for Thymoma in Suspected Ocular Myasthenia Gravis: A Retrospective Study (.pdf) [PDF]
, 2016 Thymoma can be associated with ocular myasthenia gravis (OMG).
Sui H. Wong
core
Case Report: Use of telitacicept for ocular myasthenia gravis. [PDF]
Front ImmunolYang A, Zhao J, Li F, Pang R, Zang W.
europepmc +1 more source